These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36349313)

  • 1. GRWR Correlates with the Metabolism of Tacrolimus after Pediatric Living Donor Liver Transplantation According to Donor CYP3A5 Polymorphism.
    Wan P; Hou Y; Qiu B; Feng M; Yang T; Luo Y; Xia L; Chen X; Zhang J; Xue F; Xia Q
    Biomed Res Int; 2022; 2022():7647754. PubMed ID: 36349313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of CYP3A5 genotype of recipients as well as donors on the tacrolimus pharmacokinetics and infectious complications after living-donor liver transplantation for Japanese adult recipients.
    Muraki Y; Usui M; Isaji S; Mizuno S; Nakatani K; Yamada T; Iwamoto T; Uemoto S; Nobori T; Okuda M
    Ann Transplant; 2011; 16(4):55-62. PubMed ID: 22210422
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.
    Pinon M; De Nicolò A; Pizzol A; Antonucci M; D'Avolio A; Serpe L; Dell'Olio D; Catalano S; Tandoi F; Romagnoli R; Canaparo R; Calvo PL
    Sci Rep; 2021 Jan; 11(1):443. PubMed ID: 33432012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP3A5 genotypes affect tacrolimus pharmacokinetics and infectious complications in Chinese pediatric liver transplant patients.
    Xue F; Han L; Chen Y; Xi Z; Li Q; Xu N; Xia Y; Streicher K; Zhang J; Xia Q
    Pediatr Transplant; 2014 Mar; 18(2):166-76. PubMed ID: 24438215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP3A5 genotypes on tacrolimus dose requirement: age and its pharmacological interaction with ABCB1 genetics in the Chinese paediatric liver transplantation.
    Yang TH; Chen YK; Xue F; Han LZ; Shen CH; Zhou T; Luo Y; Zhang JJ; Xia Q
    Int J Clin Pract Suppl; 2015 May; (183):53-62. PubMed ID: 26176181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation.
    Goto M; Masuda S; Kiuchi T; Ogura Y; Oike F; Okuda M; Tanaka K; Inui K
    Pharmacogenetics; 2004 Jul; 14(7):471-8. PubMed ID: 15226679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.
    Kou K; Sun X; Li M; Li T; Hu Y; Li S; Lv G
    J Clin Pharm Ther; 2022 Feb; 47(2):200-210. PubMed ID: 34708436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Influence of CYP3A5 Gene Polymorphism on Pharmacokinetics of Tacrolimus and Patient Outcome After Living Donor Liver Transplantation.
    Kato H; Usui M; Muraki Y; Tanemura A; Murata Y; Kuriyama N; Azumi Y; Kishiwada M; Mizuno S; Sakurai H; Okuda M; Nakatani K; Isaji S
    Transplant Proc; 2016 May; 48(4):1087-94. PubMed ID: 27320564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation.
    Ji E; Choi L; Suh KS; Cho JY; Han N; Oh JM
    Transplantation; 2012 Oct; 94(8):866-72. PubMed ID: 22992768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
    Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
    Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver Transplant Patient Carriers of Polymorphism Cyp3a5*1 Donors May Need More Doses of Tacrolimus From the First Month After Transplantation.
    Argudo A; González de Aledo JM; Alía P; Ramírez P; Serrano T; Fabregat J; Castellote J
    Transplant Proc; 2015 Oct; 47(8):2388-92. PubMed ID: 26518936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of
    Nakamura T; Fukuda M; Matsukane R; Suetsugu K; Harada N; Yoshizumi T; Egashira N; Mori M; Masuda S
    Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32225074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of a Once-Daily Dose of Tacrolimus Early After Liver Transplantation: With Special Reference to CYP3A5 and ABCB1 Single Nucleotide Polymorphisms.
    Miyata Y; Akamatsu N; Sugawara Y; Kaneko J; Yamamoto T; Suzuki H; Arita J; Sakamoto Y; Hasegawa K; Tamura S; Kokudo N
    Ann Transplant; 2016 Aug; 21():491-9. PubMed ID: 27503662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized tacrolimus dose requirement by CYP3A5 but not ABCB1 or ACE genotyping in both recipient and donor after pediatric liver transplantation.
    Chen YK; Han LZ; Xue F; Shen CH; Lu J; Yang TH; Zhang JJ; Xia Q
    PLoS One; 2014; 9(10):e109464. PubMed ID: 25310192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation.
    Yu S; Wu L; Jin J; Yan S; Jiang G; Xie H; Zheng S
    Transplantation; 2006 Jan; 81(1):46-51. PubMed ID: 16421475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of donor-recipient combinational CYP3A5 genotypes on tacrolimus dosing in Chinese DDLT adult recipients.
    Liu J; Chen D; Yao B; Guan G; Liu C; Jin X; Wang X; Liu P; Sun Y; Zang Y
    Int Immunopharmacol; 2020 Mar; 80():106188. PubMed ID: 31931373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intestinal CYP3A5 on postoperative tacrolimus trough levels in living-donor liver transplant recipients.
    Uesugi M; Masuda S; Katsura T; Oike F; Takada Y; Inui K
    Pharmacogenet Genomics; 2006 Feb; 16(2):119-27. PubMed ID: 16424824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.
    Wu Y; Fang F; Wang Z; Wen P; Fan J
    Eur J Clin Pharmacol; 2021 Jun; 77(6):859-867. PubMed ID: 33386894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP3A5 polymorphisms and their effects on tacrolimus exposure in an ethnically diverse South African renal transplant population.
    Muller WK; Dandara C; Manning K; Mhandire D; Ensor J; Barday Z; Freercks R
    S Afr Med J; 2020 Jan; 110(2):159-166. PubMed ID: 32657689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis and systematic review of the effect of the donor and recipient CYP3A5 6986A>G genotype on tacrolimus dose requirements in liver transplantation.
    Rojas LE; Herrero MJ; Bosó V; García-Eliz M; Poveda JL; Librero J; Aliño SF
    Pharmacogenet Genomics; 2013 Oct; 23(10):509-17. PubMed ID: 23873120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.